Apogee Therapeutics
APGE
139 hedge funds and large institutions have $2.13B invested in Apogee Therapeutics in 2024 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 40 reducing their positions, and 33 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 40
3% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 33
0% more funds holding
Funds holding: 139 → 139 (0)
0.01% less ownership
Funds ownership: 120.43% → 120.42% (-0.01%)
39% less capital invested
Capital invested by funds: $3.52B → $2.13B (-$1.39B)
64% less funds holding in top 10
Funds holding in top 10: 11 → 4 (-7)
87% less call options, than puts
Call options by funds: $87K | Put options by funds: $652K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$37M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$26.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$18.8M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$64.2M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$55.3M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$26.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$20.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.5M |
APGE Hedge Fund Activity: Q2 2024 in Review
139 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q2 2024, worth a combined $2.13B — down 39% from $3.52B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new APGE positions and 33 closed out — a net gain of 1 holder — while 48 added to existing stakes and 40 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $62M. The largest seller was Deep Track Capital, cutting an estimated $64.2M.
- 139 institutional investors held Apogee Therapeutics (APGE) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $2.13B of Apogee Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
- 34 funds opened new Apogee Therapeutics positions in Q2 2024 and 33 closed out, a net change of +1 holder.
- The largest Apogee Therapeutics buyer in Q2 2024 was Wellington Management Group, an estimated $62M added.
- The largest Apogee Therapeutics seller in Q2 2024 was Deep Track Capital, an estimated $64.2M sold.
Based on aggregated 13F filings for Q2 2024.